link
Bookmarks
Sentinel Lymph Node Biopsy
Dalliah M. Black, MD, FACSKatherine McElroy, BAHenry M. Kuerer, MD, PhD, FACS
To access 4,300 diagnoses written by the world's leading experts in radiology.Try it free - 15 days
0
0

KEY FACTS

  • Terminology

    • Preprocedure

      • Procedure

        • Post Procedure

          TERMINOLOGY

          • Definitions

            • Axillary lymph node dissection (ALND): Removal of level I and II axillary nodes
            • Sentinel lymph node (SLN) biopsy (SLNB): Surgical removal of 1st/primary draining node(s) for staging clinically node-negative breast cancer patients
              • Premise: Breast cancer will spread to 1 or a few sentinel nodes in regional nodal basin before spreading to any other nodes
              • If SLN is negative, 2-5% chance of additional node involvement [= false-negative rate (FNR)]
                • No difference in axillary recurrence rates, no need for ALND
            • Identified by uptake of Tc-99m sulfur colloid ± blue dye ± intraoperative palpation
            • Immunohistochemistry (IHC): Use of antibody to cytokeratin (present in epithelial cells) to identify isolated tumor cells (ITC)
            • Lymphoscintigraphy: Preoperative gamma imaging following injection of Tc-99m sulfur colloid into breast to evaluate lymphatic drainage and SLN location
            • 8th Edition Node Staging
              • pN0: No regional lymph node metastasis or ITCs only
              • pN0(i+): ITCs only with cluster < 0.2 mm
              • pN1: Micrometastasis (> 0.2 mm and < 2.0 mm) or metastasis in 1-3 axillary nodes or metastasis in ipsilateral IM SLN
              • pN2: Metastasis in 4-9 axillary nodes or metastasis in IM node with negative axillary node
              • pN3: Metastasis in 10 or more axillary nodes or in ipsilateral supraclavicular/infraclavicular node
            • Nonsentinel node (NSN): Lymph node not identified by blue dye or Tc-99m sulfur colloid
            • False-negative SLN: NSN with metastasis when SLN negative
            • Targeted axillary dissection (TAD): Localization and excision of known, clipped, metastatic node in addition to 2 SLN [usually after neoadjuvant chemotherapy (NAC)]
            • Clinically suspicious nodes: By physical exam &/or US
          • Location

            • SLN in ipsilateral axillary location in ~ 92-97% of patients
            • Internal mammary node (IMN) and axillary SLN in ~ 14-20%
            • Isolated IMN drainage in 2-8%
              • Isolated IMN metastasis in 1-3% of all patients
            • Isolated contralateral axillary and supraclavicular sentinel node(s) rare

          PREPROCEDURE

          • Indications

            • Contraindications

              • Getting Started

                PROCEDURE

                • Patient Position/Location

                  • Procedure Steps

                    • Findings and Reporting

                      • Alternative Procedures/Therapies

                        POST PROCEDURE

                        • Expected Outcome

                          • Things to Do

                            OUTCOMES

                            • Complications

                              Selected References

                              1. Moossdorff M et al: The potential impact of AMAROS on the management of the axilla in patients with clinical T1-2N0 breast cancer undergoing primary total mastectomy. Ann Surg Oncol. 25(9):2612-19, 2018
                              2. Reimer T et al: Is axillary sentinel lymph node biopsy required in patients who undergo primary breast surgery? Breast Care (Basel). 13(5):324-30, 2018
                              3. Yan M et al: Axillary management in breast cancer patients: a comprehensive review of the key trials. Clin Breast Cancer. 18(6):e1251-e1259, 2018
                              4. Giuliano AE et al: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 318(10):918-26, 2017
                              5. Lyman GH et al: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 35(5):561-4, 2017
                              6. Boughey JC et al: Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 263(4):802-7, 2016
                              7. Donker M et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 15(12):1303-10, 2014
                              8. Boughey JC et al: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 310(14):1455-61, 2013
                              9. Alvarado R et al: The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 19(10):3177-84, 2012
                              10. Milgrom S et al: Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 19(12):3762-70, 2012
                              11. Mittendorf EA et al: Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 255(1):109-15, 2012
                              12. Shah C et al: Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment AIDS, treatment paradigms, and risk reduction. Breast J. 18(4):357-61, 2012
                              13. Takahashi M et al: Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy. World J Surg. 36(12):2847-52, 2012
                              14. Giuliano AE et al: Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 306(4):385-93, 2011
                              15. Giuliano AE et al: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 305(6):569-75, 2011
                              16. Tan VK et al: The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis. J Surg Oncol. 104(1):97-103, 2011
                              17. Krag DN et al: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 11(10):927-33, 2010
                              18. Sharma R et al: Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 17(11):2899-908, 2010
                              19. Veronesi U et al: Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 251(4):595-600, 2010
                              20. Hunt KK et al: Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 250(4):558-66, 2009
                              21. Macdonald SM et al: Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 75(5):1297-303, 2009
                              22. Bevilacqua JL et al: Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 25(24):3670-9, 2007
                              23. Krag DN et al: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8(10):881-8, 2007
                              24. Kim T et al: Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 106(1):4-16, 2006
                              25. Mansel RE et al: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 98(9):599-609, 2006
                              26. Wilke LG et al: Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 13(4):491-500, 2006
                              27. Lyman GH et al: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 23(30):7703-20, 2005
                              28. Specht MC et al: Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 12(8):654-9, 2005
                              29. Truong PT et al: Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 61(5):1337-47, 2005
                              30. Balch GC et al: Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 10(6):616-21, 2003
                              Related Anatomy
                              Loading...
                              Related Differential Diagnoses
                              Loading...
                              References
                              Tables

                              Tables

                              KEY FACTS

                              • Terminology

                                • Preprocedure

                                  • Procedure

                                    • Post Procedure

                                      TERMINOLOGY

                                      • Definitions

                                        • Axillary lymph node dissection (ALND): Removal of level I and II axillary nodes
                                        • Sentinel lymph node (SLN) biopsy (SLNB): Surgical removal of 1st/primary draining node(s) for staging clinically node-negative breast cancer patients
                                          • Premise: Breast cancer will spread to 1 or a few sentinel nodes in regional nodal basin before spreading to any other nodes
                                          • If SLN is negative, 2-5% chance of additional node involvement [= false-negative rate (FNR)]
                                            • No difference in axillary recurrence rates, no need for ALND
                                        • Identified by uptake of Tc-99m sulfur colloid ± blue dye ± intraoperative palpation
                                        • Immunohistochemistry (IHC): Use of antibody to cytokeratin (present in epithelial cells) to identify isolated tumor cells (ITC)
                                        • Lymphoscintigraphy: Preoperative gamma imaging following injection of Tc-99m sulfur colloid into breast to evaluate lymphatic drainage and SLN location
                                        • 8th Edition Node Staging
                                          • pN0: No regional lymph node metastasis or ITCs only
                                          • pN0(i+): ITCs only with cluster < 0.2 mm
                                          • pN1: Micrometastasis (> 0.2 mm and < 2.0 mm) or metastasis in 1-3 axillary nodes or metastasis in ipsilateral IM SLN
                                          • pN2: Metastasis in 4-9 axillary nodes or metastasis in IM node with negative axillary node
                                          • pN3: Metastasis in 10 or more axillary nodes or in ipsilateral supraclavicular/infraclavicular node
                                        • Nonsentinel node (NSN): Lymph node not identified by blue dye or Tc-99m sulfur colloid
                                        • False-negative SLN: NSN with metastasis when SLN negative
                                        • Targeted axillary dissection (TAD): Localization and excision of known, clipped, metastatic node in addition to 2 SLN [usually after neoadjuvant chemotherapy (NAC)]
                                        • Clinically suspicious nodes: By physical exam &/or US
                                      • Location

                                        • SLN in ipsilateral axillary location in ~ 92-97% of patients
                                        • Internal mammary node (IMN) and axillary SLN in ~ 14-20%
                                        • Isolated IMN drainage in 2-8%
                                          • Isolated IMN metastasis in 1-3% of all patients
                                        • Isolated contralateral axillary and supraclavicular sentinel node(s) rare

                                      PREPROCEDURE

                                      • Indications

                                        • Contraindications

                                          • Getting Started

                                            PROCEDURE

                                            • Patient Position/Location

                                              • Procedure Steps

                                                • Findings and Reporting

                                                  • Alternative Procedures/Therapies

                                                    POST PROCEDURE

                                                    • Expected Outcome

                                                      • Things to Do

                                                        OUTCOMES

                                                        • Complications

                                                          Selected References

                                                          1. Moossdorff M et al: The potential impact of AMAROS on the management of the axilla in patients with clinical T1-2N0 breast cancer undergoing primary total mastectomy. Ann Surg Oncol. 25(9):2612-19, 2018
                                                          2. Reimer T et al: Is axillary sentinel lymph node biopsy required in patients who undergo primary breast surgery? Breast Care (Basel). 13(5):324-30, 2018
                                                          3. Yan M et al: Axillary management in breast cancer patients: a comprehensive review of the key trials. Clin Breast Cancer. 18(6):e1251-e1259, 2018
                                                          4. Giuliano AE et al: Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 318(10):918-26, 2017
                                                          5. Lyman GH et al: Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 35(5):561-4, 2017
                                                          6. Boughey JC et al: Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 263(4):802-7, 2016
                                                          7. Donker M et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 15(12):1303-10, 2014
                                                          8. Boughey JC et al: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 310(14):1455-61, 2013
                                                          9. Alvarado R et al: The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 19(10):3177-84, 2012
                                                          10. Milgrom S et al: Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment. Ann Surg Oncol. 19(12):3762-70, 2012
                                                          11. Mittendorf EA et al: Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 255(1):109-15, 2012
                                                          12. Shah C et al: Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment AIDS, treatment paradigms, and risk reduction. Breast J. 18(4):357-61, 2012
                                                          13. Takahashi M et al: Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy. World J Surg. 36(12):2847-52, 2012
                                                          14. Giuliano AE et al: Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 306(4):385-93, 2011
                                                          15. Giuliano AE et al: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 305(6):569-75, 2011
                                                          16. Tan VK et al: The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer--a systematic review and meta-analysis. J Surg Oncol. 104(1):97-103, 2011
                                                          17. Krag DN et al: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 11(10):927-33, 2010
                                                          18. Sharma R et al: Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 17(11):2899-908, 2010
                                                          19. Veronesi U et al: Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 251(4):595-600, 2010
                                                          20. Hunt KK et al: Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 250(4):558-66, 2009
                                                          21. Macdonald SM et al: Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 75(5):1297-303, 2009
                                                          22. Bevilacqua JL et al: Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J Clin Oncol. 25(24):3670-9, 2007
                                                          23. Krag DN et al: Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 8(10):881-8, 2007
                                                          24. Kim T et al: Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 106(1):4-16, 2006
                                                          25. Mansel RE et al: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 98(9):599-609, 2006
                                                          26. Wilke LG et al: Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 13(4):491-500, 2006
                                                          27. Lyman GH et al: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 23(30):7703-20, 2005
                                                          28. Specht MC et al: Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 12(8):654-9, 2005
                                                          29. Truong PT et al: Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 61(5):1337-47, 2005
                                                          30. Balch GC et al: Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 10(6):616-21, 2003